{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:58Z","timestamp":1791397378399,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04576-z","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:54:19Z","timestamp":1757577259000},"page":"2765-2796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design and synthesis of novel Osimertinib analogs for dual EGFR and P-glycoprotein 1 inhibition targeting multidrug resistance in non-small cell lung cancer: In vitro and in vivo evaluation"],"prefix":"10.1007","volume":"399","author":[{"given":"Harikrishna","family":"Akkapelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya Sagar","family":"Jerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appaji","family":"Dokala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"4576_CR1","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1126\/science.1168750","volume":"323","author":"SG Aller","year":"2009","unstructured":"Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718\u20131723. https:\/\/doi.org\/10.1126\/science.1168750","journal-title":"Science"},{"key":"4576_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0163-7258(98)00078-8","volume":"82","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) P-glycoprotein: from membrane to bedside. Pharmacol Ther 82:111\u2013133. https:\/\/doi.org\/10.1016\/S0163-7258(98)00078-8","journal-title":"Pharmacol Ther"},{"key":"4576_CR3","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","volume":"22","author":"SV Ambudkar","year":"2003","unstructured":"Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468\u20137485. https:\/\/doi.org\/10.1038\/sj.onc.1206948","journal-title":"Oncogene"},{"key":"4576_CR4","volume-title":"Cancer facts & figures 2023","author":"American Cancer Society","year":"2023","unstructured":"American Cancer Society (2023) Cancer facts & figures 2023. American Cancer Society, Atlanta"},{"key":"4576_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/hesc\/9780199270293.001.0001","volume-title":"Organic chemistry","author":"J Clayden","year":"2012","unstructured":"Clayden J, Greeves N, Warren S (2012) Aromatic heterocycles. In: Clayden J, Greeves N, Warren S, Wothers P (eds) Organic chemistry, 2nd edn. Oxford University Press, Oxford, pp 573\u2013598","edition":"2"},{"key":"4576_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046\u20131061. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0337","journal-title":"Cancer Discov"},{"key":"4576_CR7","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"4576_CR8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3390\/molecules24132407","volume":"24","author":"H Dong","year":"2019","unstructured":"Dong H, Yin H, Zhao C, Cao J, Xu W, Zhang Y (2019) Design, synthesis and biological evaluation of novel OSB-based HDAC and EGFR dual inhibitors. Molecules 24:2407. https:\/\/doi.org\/10.3390\/molecules24132407","journal-title":"Molecules"},{"key":"4576_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.phrs.2019.04.012","volume":"144","author":"Y D\u00f6nmez Cakil","year":"2019","unstructured":"D\u00f6nmez Cakil Y, Bolukbasi S, Cakil O, Dundar Y (2019) P-glycoprotein inhibition: promising approach for overcoming multidrug resistance in cancer. Pharmacol Res 144:280\u2013294. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.012","journal-title":"Pharmacol Res"},{"key":"4576_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495\u2013516. https:\/\/doi.org\/10.1080\/01926230701320337","journal-title":"Toxicol Pathol"},{"key":"4576_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cancers11081160","volume":"11","author":"K Fujita","year":"2019","unstructured":"Fujita K, Masuda S, Sugiyama T (2019) The role of ABCG2 in cancer chemotherapy: resistance and regulation. Cancers (Basel) 11:1160. https:\/\/doi.org\/10.3390\/cancers11081160","journal-title":"Cancers (Basel)"},{"key":"4576_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1083\/jcb.119.3.493","volume":"119","author":"Y Gavrieli","year":"1992","unstructured":"Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493\u2013501. https:\/\/doi.org\/10.1083\/jcb.119.3.493","journal-title":"J Cell Biol"},{"key":"4576_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48\u201358. https:\/\/doi.org\/10.1038\/nrc706","journal-title":"Nat Rev Cancer"},{"key":"4576_CR14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u2013726. https:\/\/doi.org\/10.1038\/nrc3599","journal-title":"Nat Rev Cancer"},{"key":"4576_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1021\/acs.molpharmaceut.6b00249","volume":"13","author":"SH Hsiao","year":"2016","unstructured":"Hsiao SH, Lu YJ, Li YQ, Huang YH, Hsieh CH, Wu CP (2016) OSB (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in vitro. Mol Pharm 13:2117\u20132125. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00249","journal-title":"Mol Pharm"},{"key":"4576_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/bjc.1972.33","volume":"26","author":"JF Kerr","year":"1972","unstructured":"Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239\u2013257. https:\/\/doi.org\/10.1038\/bjc.1972.33","journal-title":"Br J Cancer"},{"key":"4576_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.lungcan.2005.03.035","volume":"49","author":"T Kitazaki","year":"2005","unstructured":"Kitazaki T, Suzuki A, Sasaki K, Sato S, Matsuura N, Kanda A, Sugihara K, Kasai H, Akasaka K, Terasaka T (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49:337\u2013343. https:\/\/doi.org\/10.1016\/j.lungcan.2005.03.035","journal-title":"Lung Cancer"},{"key":"4576_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2009","unstructured":"Kroemer G, Galluzzi L, Brenner C (2009) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99\u2013163. https:\/\/doi.org\/10.1152\/physrev.00013.2006","journal-title":"Physiol Rev"},{"key":"4576_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bcp.2009.08.021","volume":"79","author":"YH Kuang","year":"2010","unstructured":"Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JK, Fu LW, Chen ZS (2010) Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 79:154\u2013161. https:\/\/doi.org\/10.1016\/j.bcp.2009.08.021","journal-title":"Biochem Pharmacol"},{"key":"4576_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fonc.2020.00369","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Wang C, Zhu J, Wu X (2020) Advances in targeted therapy for NSCLC: focus on EGFR mutations and ALK rearrangements. Front Oncol 10:369. https:\/\/doi.org\/10.3389\/fonc.2020.00369","journal-title":"Front Oncol"},{"key":"4576_CR21","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1021\/cr00039a007","volume":"95","author":"N Miyaura","year":"1995","unstructured":"Miyaura N, Suzuki A (1995) Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem Rev 95:2457\u20132483. https:\/\/doi.org\/10.1021\/cr00039a007","journal-title":"Chem Rev"},{"key":"4576_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ et al (2017) OSB or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"4576_CR23","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1016\/j.tet.2005.08.031","volume":"61","author":"CAGN Montalbetti","year":"2005","unstructured":"Montalbetti CAGN, Falque V (2005) Amide bond formation and peptide coupling. Tetrahedron 61:10827\u201310852. https:\/\/doi.org\/10.1016\/j.tet.2005.08.031","journal-title":"Tetrahedron"},{"key":"4576_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"4576_CR25","unstructured":"National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer. Version 2.2023. NCCN.org. Available at\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf.\u00a0Accessed 15 Jul 2025"},{"key":"4576_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/0471224480","volume-title":"The nitro group in organic synthesis","author":"N Ono","year":"2001","unstructured":"Ono N (2001) The nitro group in organic synthesis. Wiley-VCH, Weinheim"},{"key":"4576_CR27","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1158\/0008-5472.CAN-04-2326","volume":"64","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Heged\u0171s T, Varga A, Ujhelly O, Schuetz JD, V\u00e1radi A, Sarkadi B (2004) High-affinity binding of tyrosine kinase inhibitors to human ABCB1: implications for the treatment of tumors. Cancer Res 64:8637\u20138643. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2326","journal-title":"Cancer Res"},{"key":"4576_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/biomedicines9040439","volume":"9","author":"A Pezzuto","year":"2021","unstructured":"Pezzuto A, Mariotta S, Mazzuca F (2021) New insights into mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer. Biomedicines 9:439. https:\/\/doi.org\/10.3390\/biomedicines9040439","journal-title":"Biomedicines"},{"key":"4576_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.02299","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40:586\u2013597. https:\/\/doi.org\/10.1200\/JCO.21.02299","journal-title":"J Clin Oncol"},{"key":"4576_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18:452\u2013464. https:\/\/doi.org\/10.1038\/s41568-018-0005-8","journal-title":"Nat Rev Cancer"},{"key":"4576_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG (2017) Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17:637\u2013658. https:\/\/doi.org\/10.1038\/nrc.2017.84","journal-title":"Nat Rev Cancer"},{"key":"4576_CR32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","volume":"86","author":"B Sarkadi","year":"2006","unstructured":"Sarkadi B, Homolya L, Szak\u00e1cs G, V\u00e1radi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179\u20131236. https:\/\/doi.org\/10.1152\/physrev.00037.2005","journal-title":"Physiol Rev"},{"key":"4576_CR33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ejmech.2017.07.039","volume":"138","author":"S Seetharaman","year":"2017","unstructured":"Seetharaman S, Barile E, Gewirtz DA (2017) Dual inhibitors of EGFR and P-gp: a promising approach to overcome multidrug resistance in cancer. Eur J Med Chem 138:994\u20131008. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.039","journal-title":"Eur J Med Chem"},{"key":"4576_CR34","doi-asserted-by":"publisher","first-page":"11012","DOI":"10.1158\/0008-5472.CAN-07-2686","volume":"67","author":"Z Shi","year":"2007","unstructured":"Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS (2007) Erlotinib antagonizes ABCB1- and ABCG2-mediated drug resistance. Cancer Res 67:11012\u201311020. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2686","journal-title":"Cancer Res"},{"key":"4576_CR35","first-page":"857","volume-title":"March\u2019s advanced organic chemistry","author":"MB Smith","year":"2013","unstructured":"Smith MB (2013) Nucleophilic aromatic substitution. In: Smith MB (ed) March\u2019s advanced organic chemistry, 7th edn. Wiley, Hoboken, pp 857\u2013892","edition":"7"},{"key":"4576_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH (2018) Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"4576_CR37","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","volume":"26","author":"T Stankovi\u0107","year":"2019","unstructured":"Stankovi\u0107 T, Dini\u0107 J, Podolski-Reni\u0107 A, Musso L, Pe\u0161i\u0107 M, Pavlovi\u0107 S (2019) Dual inhibitors as a new challenge for cancer multidrug resistance treatment. Curr Med Chem 26:6074\u20136106. https:\/\/doi.org\/10.2174\/0929867325666180607094856","journal-title":"Curr Med Chem"},{"key":"4576_CR38","volume-title":"Indoles","author":"RJ Sundberg","year":"1996","unstructured":"Sundberg RJ (1996) Indoles. Academic Press, San Diego"},{"key":"4576_CR39","doi-asserted-by":"publisher","first-page":"591009","DOI":"10.3389\/fphar.2020.591009","volume":"11","author":"E Thomas","year":"2020","unstructured":"Thomas E, Coley HM (2020) Overcoming multidrug resistance in cancer: recent progress in nanoparticle-based drug delivery systems. Front Pharmacol 11:591009. https:\/\/doi.org\/10.3389\/fphar.2020.591009","journal-title":"Front Pharmacol"},{"key":"4576_CR40","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","volume":"76","author":"H Towbin","year":"1979","unstructured":"Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350\u20134354. https:\/\/doi.org\/10.1073\/pnas.76.9.4350","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4576_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fphar.2019.00412","volume":"10","author":"Y Toyoda","year":"2019","unstructured":"Toyoda Y, Takada T, Suzuki H (2019) Inhibitors of human ABCG2: from technical background to recent updates with clinical implications. Front Pharmacol 10:412. https:\/\/doi.org\/10.3389\/fphar.2019.00412","journal-title":"Front Pharmacol"},{"key":"4576_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"4576_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575:299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1","journal-title":"Nature"},{"key":"4576_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled Annexin V. J Immunol Methods 184:39\u201351. https:\/\/doi.org\/10.1016\/0022-1759(95)00072-I","journal-title":"J Immunol Methods"},{"key":"4576_CR45","doi-asserted-by":"publisher","first-page":"676361","DOI":"10.3389\/fphar.2021.676361","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Song X, Chen W, Lu J (2021) Targeting drug-resistant cancer: from molecular mechanisms to novel treatment strategies. Front Pharmacol 12:676361. https:\/\/doi.org\/10.3389\/fphar.2021.676361","journal-title":"Front Pharmacol"},{"key":"4576_CR46","doi-asserted-by":"publisher","first-page":"16768","DOI":"10.18632\/oncotarget.7865","volume":"7","author":"CP Wu","year":"2016","unstructured":"Wu CP, Hsieh CH, Wu YS, Yang SC, Chen YJ, Whang-Peng J (2016) Co-targeting EGFR with P-glycoprotein effectively overcomes erlotinib resistance in non-small cell lung cancer cells. Oncotarget 7:16768\u201316783. https:\/\/doi.org\/10.18632\/oncotarget.7865","journal-title":"Oncotarget"},{"key":"4576_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/284555a0","volume":"284","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555\u2013556. https:\/\/doi.org\/10.1038\/284555a0","journal-title":"Nature"},{"key":"4576_CR48","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2174\/1381612824666180510122444","volume":"24","author":"Y Xu","year":"2018","unstructured":"Xu Y, Liu H, Wang Y (2018) Advances in overcoming drug resistance in lung cancer. Curr Pharm des 24:1711\u20131721. https:\/\/doi.org\/10.2174\/1381612824666180510122444","journal-title":"Curr Pharm des"},{"key":"4576_CR49","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"CH Yun","year":"2008","unstructured":"Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070\u20132075. https:\/\/doi.org\/10.1073\/pnas.0709662105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4576_CR50","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.04.020","volume":"125","author":"X Zhang","year":"2006","unstructured":"Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of EGFR. Cell 125:1137\u20131149. https:\/\/doi.org\/10.1016\/j.cell.2006.04.020","journal-title":"Cell"},{"key":"4576_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jcb.26194","volume":"119","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang CY, Duan YJ, Huo XK, Meng Q, Liu ZH, Sun HJ, Ma XD, Liu KX (2018) Afatinib decreases P-glycoprotein expression to promote Adriamycin toxicity of A549T cells. J Cell Biochem 119:414\u2013423. https:\/\/doi.org\/10.1002\/jcb.26194","journal-title":"J Cell Biochem"},{"key":"4576_CR52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.yexcr.2017.02.016","volume":"352","author":"HC Zheng","year":"2017","unstructured":"Zheng HC, Wu D (2017) Stepwise dose-escalation strategy for establishing drug-resistant cancer cell lines: a detailed methodology. Exp Cell Res 352:321\u2013328. https:\/\/doi.org\/10.1016\/j.yexcr.2017.02.016","journal-title":"Exp Cell Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04576-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:47:45Z","timestamp":1770882465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04576-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04576-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"During the preparation of this study, the author(s) utilized ChatGPT to enhance language clarity and readability. Following the use of this tool, the author(s) thoroughly reviewed and revised the content to ensure accuracy and to take full responsibility for the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies"}}]}}